24/7 Market News Snapshot 28 March, 2025 – Quantum Biopharma Ltd. Class B Subordinate Voting Shares (NASDAQ:QNTM)

March 28, 2025

DENVER, Colo., 28 March, 2025 (247marketnews.com) – (NASDAQ:QNTM) are discussed in this article.
Quantum Biopharma Ltd. (NASDAQ:QNTM) is experiencing a significant surge in market performance, with its Class B Subordinate Voting Shares soaring from a previous close of $8.380 to an impressive $10.821, reflecting a remarkable 29.13% increase during today’s trading session. The stock has recorded a volume of 2.59 million shares, indicating strong bullish sentiment among investors as excitement builds around potential breakthroughs within the biotechnology sector.

The company has not only shown dramatic gains in stock performance, but it has also reported an impressive financial outlook for the year ending December 31, 2024. Quantum Biopharma’s cash position has risen to $12.1 million, up from $11.1 million the previous year, showcasing enhanced financial resilience. Strategic cost management initiatives have led to a noteworthy 32% reduction in operating expenses, reinforcing its commitment to sustainability and effective resource utilization.

Significantly, Quantum Biopharma has made remarkable strides in product development, including the introduction of unbuzzd—a pioneering dietary supplement that accelerates the detoxification process from alcohol. Results from a double-blind, randomized clinical trial revealed that unbuzzd significantly reduced blood alcohol concentration by over 40% within just 30 minutes—data that supports its promising market entry through a newly inked master distribution agreement with FUSION Distribution Group.

Additionally, the company is advancing its innovative treatment for multiple sclerosis, Lucid-21-302, which has successfully completed Phase 1 trials showcasing a favorable safety profile. This first-in-class neuroprotective therapy aims to redefine treatment for MS and is set to enter Phase 2 trials shortly.

CEO Zeeshan Saeed reaffirmed the company’s dedication to addressing critical health challenges while generating shareholder value through its pipeline and strategic partnerships. As Quantum Biopharma positions itself for transformational growth, its commitment to pioneering solutions continues to take center stage in the biopharmaceutical landscape.

Related news for (QNTM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.